Publications

Found 533 results
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Madhukar NS, Elemento O, Pandey G.  2015.  Prediction of Genetic Interactions Using Machine Learning and Network Properties.. Front Bioeng Biotechnol. 3:172.
Bai Z, Osman M, Brendel M, Tangen CM, Flaig TW, Thompson IM, Plets M, M Lucia S, Theodorescu D, Gustafson D et al..  2025.  Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning.. NPJ Digit Med. 8(1):174.
Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.
Charilaou P, Mohapatra S, Doukas S, Kohli M, Radadiya D, Devani K, Broder A, Elemento O, Lukin DJ, Battat R.  2023.  Predicting inpatient mortality in patients with inflammatory bowel disease: A machine learning approach.. J Gastroenterol Hepatol. 38(2):241-250.
Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Camarillo JM, Mehta S, Chen EI et al..  2019.  Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.. Clin Cancer Res. 25(17):5271-5283.
Hajirasouliha I, Elemento O.  2020.  Precision medicine and artificial intelligence: overview and relevance to reproductive medicine.. Fertil Steril. 114(5):908-913.
Carty MA, Elemento O.  2016.  Practical Analysis of Genome Contact Interaction Experiments.. Methods Mol Biol. 1418:177-89.
Glass J, Elemento O.  2024.  The power and perils of large language models in haematology.. Br J Haematol. 205(6):2190-2192.
Kandola MS, Kulm S, Kim LK, Markowitz SM, Liu CF, Thomas G, Ip JE, Lerman BB, Elemento O, Cheung JW.  2023.  Population-Level Prevalence of Rare Variants Associated With Atrial Fibrillation and its Impact on Patient Outcomes.. JACC Clin Electrophysiol. 9(7 Pt 2):1137-1146.
De Boni L, Claridge S, Nath S, Tofani K, Stein BD, Park E, Steiner S, Elemento O, Pauli C, Hopkins BD.  2026.  Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors.. iScience. 29(3):114954.
Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Ravi A, Verma A, Yang Z et al..  2018.  Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.. Mol Cell. 70(3):531-544.e9.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
Rendeiro AF, Ravichandran H, Kim J, Borczuk AC, Elemento O, Schwartz RE.  2022.  Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19.. medRxiv.
Park K, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T, Borczuk A, Mosquera JMiguel, Pan Q, Sboner A et al..  2020.  Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med.
K Devi SP, Wang E, Jaiswal A, Konieczny P, Kim T-G, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN et al..  2025.  PD-1 is requisite for skin T cell formation and specification by TGFβ.. Nat Immunol. 26(8):1339-1351.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B et al..  2024.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. Cancer Lett. 584:216608.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK et al..  2023.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. bioRxiv.
Fiore D, Cappelli LVincenzo, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A et al..  2025.  A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.. Cell Rep Med. 6(4):102029.
Kuo H-H, Bhinder B, Gokozan HN, Gorski K, Chandra P, Manohar J, Guevara D, Otilano J, Moyer J, Tranquille M et al..  2026.  Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.. Sci Adv. 12(26):eadz3351.
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.
Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R et al..  2012.  A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.. Clin Cancer Res. 18(7):2032-8.
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X, Moyer J, M Martin L, Chandwani R, Elemento O et al..  2024.  A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.. Cell Stem Cell. 31(1):71-88.e8.
Bhinder B, Friedl V, Sethuraman S, Risso D, Chiotti KE, R Mashl J, Ellrott KP, Lee JA, Wong CK, Gyan K et al..  2025.  Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles.. Sci Rep. 15(1):23921.
Xu C, Us I, Cohen-Setton J, Milo M, Sidders B, Fitzgibbon J, Melnick AM, Pan H, Elemento O, Bulusu KC.  2024.  PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.. bioRxiv.
Xu C, Us I, Cohen-Setton J, Milo M, Sidders B, Fitzgibbon J, Melnick AM, Pan H, Bulusu KC, Elemento O.  2026.  PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.. Res Sq.